MBX Biosciences Reports Third Quarter 2026 Financial Results and Corporate Highlights

Nine-month net loss widened to $123.033 million from $64.909 million in the same period of 2025.

Rhea-AI Summary

MBX Biosciences (MBX) reported a third-quarter 2026 net loss of $62.421 million as its pivotal canvuparatide trial advanced. The loss compared with $21.618 million a year earlier; loss per share widened to $1.29 from $0.63. Research and development expenses rose to $32.048 million, while general and administrative expenses reached $34.295 million.

Cash and investments totaled $481.594 million at September 30, including $97.6 million in net proceeds from common-stock sales. MBX expects its funds to support operations into 2029 under its current operating plan. Enrollment is underway in the Phase 3 oPTimize trial, which is expected to enroll approximately 160 adults with chronic hypoparathyroidism. MBX expects unblinded 12-week Phase 1 MBX 4291 cohort data in Q4 2026. Studies supporting applications to begin human testing remain ongoing for MBX 5765 and MBX 6180.

12 points · 0 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 8 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Moderate pointCommon-stock sales under the at-the-market agreement generated $97.6 million in net proceeds. 3.9% of market cap
• Moderate point. Forward-looking: it has not happened yet and may not happen.MBX expects its funds to support operations into 2029 under its current operating plan.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Phase 3 oPTimize enrollment is underway; the trial is expected to enroll approximately 160 adults with chronic hypoparathyroidism.
• Minor pointCash and investments increased to $481.594 million at September 30, 2026, from $373.705 million at December 31, 2025.
• Minor point. Forward-looking: it has not happened yet and may not happen.MBX 4291 unblinded 12-week Phase 1 Part C, Cohort 1 data remain on track for Q4 2026.

7 minor points

• Minor pointMBX 5765 studies supporting an application to begin human testing remain ongoing.
• Minor pointMBX 6180 studies supporting an application to begin human testing remain ongoing.
• Minor pointThird-quarter interest and other income, net, rose to $3.922 million from $2.308 million a year earlier.
• Minor pointNine-month interest and other income, net, increased to $11.506 million from $7.351 million in 2025.
• Minor pointWorking capital increased to $467.595 million at September 30, 2026, from $366.044 million at December 31, 2025.
• Minor pointTotal assets increased to $500.618 million at September 30, 2026, from $385.144 million at December 31, 2025.
• Minor pointStockholders’ equity increased to $472.947 million at September 30, 2026, from $369.223 million at December 31, 2025.

Negative

• Moderate pointThird-quarter net loss widened to $62.421 million from $21.618 million in 2025; loss per share reached $1.29 versus $0.63.
• Moderate pointCommon-stock issuance under the at-the-market agreement diluted existing shareholders.
• Minor pointThird-quarter research and development expenses increased to $32.048 million from $19.270 million a year earlier.
• Minor pointThird-quarter administrative expenses rose to $34.295 million from $4.656 million, including $20.8 million in award-modification stock compensation.
• Minor pointNine-month net loss widened to $123.033 million from $64.909 million; loss per share reached $2.58 versus $1.93.

3 minor points

• Minor pointNine-month research and development expenses increased to $81.507 million from $59.400 million in 2025.
• Minor pointNine-month general and administrative expenses increased to $53.032 million from $12.860 million in 2025.
• Minor pointTotal liabilities increased to $27.671 million at September 30, 2026, from $15.921 million at December 31, 2025.

News Explained

MBX received $97.6 million net from common-stock sales under its ATM, which lets the company sell newly issued shares gradually at market prices; the company gained cash and existing holders’ proportional ownership was diluted, though the release gives no share count to size that effect.

Key Figures

Cash, cash equivalents and marketable securities: $481.6 million ATM stock-sale proceeds: $97.6 million Cash runway: Into 2029 +5 more

Cash, cash equivalents and marketable securities

$481.6 million

As of September 30, 2026

ATM stock-sale proceeds

$97.6 million

Net proceeds reflected in the September 30, 2026 balance

Cash runway

Into 2029

Based on the company's current operating plan

R&D expenses

$32.0 million vs. $19.3 million

Three months ended September 30, 2026 vs. the same period in 2025

G&A expenses

$34.3 million vs. $4.7 million

Three months ended September 30, 2026 vs. the same period in 2025

Net loss

$62.4 million vs. $21.6 million

Three months ended September 30, 2026 vs. the same period in 2025

Phase 3 trial enrollment

Approximately 160 adults

Expected enrollment in the oPTimize trial

MBX 4291 data timing

12-week data in Q4 2026

Unblinded data from the first cohort of the Phase 1 trial

Previous Earnings Reports

2 past events · Latest: Aug 06

Same Type 2 events

1. Aug 06

   Earnings report

   24h Move

   -0.6%

   Canvuparatide Phase 3 trial was planned to initiate in Q3; cash runway extended into 2029.

2. May 07

   Earnings report

   24h Move

   +8.1%

   Canvuparatide Phase 3 start remained on track for Q3, with cash runway into 2029.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

multiple ascending dose, pharmacokinetic, at-the-market, double-blind

4 terms

multiple ascending dose medical

"first cohort of the 12-week multiple ascending dose (MAD, Part C, Cohort 1)"

A multiple ascending dose is a method used in testing new medicines where small groups of people receive gradually larger amounts of the drug over time. This approach helps researchers find the safest and most effective dose without causing too many side effects. For investors, it signals ongoing steps in drug development that can impact a company's potential success or approval prospects.

pharmacokinetic technical

"preclinical pharmacokinetic data for MBX 6180"

Pharmacokinetic describes how a drug moves through and leaves the body — how it is absorbed, spread to tissues, broken down and excreted — like tracking a package from pickup to delivery and disposal. For investors, these properties determine effective dose, safety risks, how often a medicine must be taken, and how reliably it works, which in turn influence clinical trial success, regulatory approval chances, production complexity and a drug’s commercial value.

at-the-market financial

"under the Company’s at-the-market (ATM) sales agreement"

"At-the-market" is a method for companies to sell new shares of stock directly into the open market over time, rather than all at once. It allows companies to raise money gradually, similar to selling slices of a pie instead of the entire pie at once, which can help manage the sale's impact on the stock price. This approach gives investors a steady supply of shares while providing companies with flexible funding options.

double-blind medical

"global, randomized, double-blind, placebo-controlled trial"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Enrollment in pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway

12-week MAD (Part C, Cohort 1) data for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity designed for once-monthly dosing, on track for Q4 2026

Preclinical data for MBX 6180, a GLP-1/GIP/GCG triple agonist prodrug with potential for once-monthly dosing, accepted for presentation at ObesityWeek 2026

$481.6 million in cash and investments expected to support operations into 2029

CARMEL, Ind., and BURLINGTON, Mass., Nov. 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent corporate progress.

“The third quarter marked an important milestone for MBX with the initiation of our pivotal Phase 3 oPTimize trial of once-weekly canvuparatide, a potential best-in-class PTH replacement therapy,” said Steve Hoerter, Chairman and Chief Executive Officer of MBX Biosciences. “We remain on track to report unblinded 12-week MAD Phase 1 data for MBX 4291, which is designed to deliver true once-monthly dosing and we believe has the potential to offer improved gastrointestinal tolerability. Meanwhile, we continue to advance multiple preclinical obesity programs all enabled by our clinically-validated and differentiated Precision Endocrine Peptide (PEP™) platform. With a strong balance sheet and cash runway into 2029, we believe we are well positioned to advance canvuparatide through pivotal development while continuing to invest in our growing obesity portfolio.”

Third Quarter 2026 and Corporate Highlights

Once-Weekly Canvuparatide for Hypoparathyroidism (HP)

• Pivotal Phase 3 oPTimize trial of once-weekly canvuparatide underway: In August 2026, MBX announced the dosing of the first patient in its pivotal Phase 3 oPTimize trial. The global, randomized, double-blind, placebo-controlled trial is expected to enroll approximately 160 adults with chronic hypoparathyroidism. The trial builds on positive Phase 2 Avail™ results and sustained clinical benefit demonstrated through one year of treatment in the open-label extension study.
  
  

MBX 4291 and Expanding Obesity Portfolio

• 12-week MAD (Part C) data for MBX 4291 on track for Q4 2026: Following initial Phase 1 data supporting the potential for once-monthly dosing, MBX remains on track to report unblinded data from the first cohort of the 12-week multiple ascending dose (MAD, Part C, Cohort 1) portion of its ongoing Phase 1 trial of MBX 4291. Cohort C1 is evaluating a titration regimen of 30 mg once weekly for four weeks, followed by 120 mg and 180 mg once monthly, in adult participants with a BMI ≥30 kg/m².
  
  
• IND-enabling studies ongoing for MBX 5765: MBX continues to advance MBX 5765, its amycretin prodrug candidate combining GLP-1, GIP, glucagon and dual amylin/calcitonin receptor agonist (DACRA) activity in a single peptide construct. The differentiated mechanism of MBX 5765 is designed for once-monthly dosing, with the potential for superior efficacy and improved tolerability.
  
  
• Preclinical data for MBX 6180 accepted for presentation at ObesityWeek 2026: MBX expects to present preclinical pharmacokinetic data for MBX 6180, its GLP-1/GIP/GCG triple agonist prodrug designed for once-monthly dosing, in a poster presentation at ObesityWeek 2026, taking place November 14-17, 2026, in Washington, D.C. IND-enabling studies for MBX 6180 are ongoing.
  
  

Corporate

• Appointed Peter Radovich to Board of Directors: In October 2026, MBX appointed Peter Radovich, President and Chief Operating Officer of Mirum Pharmaceuticals, to its Board of Directors. Mr. Radovich brings more than 20 years of biopharmaceutical industry experience spanning commercial operations, corporate development and program leadership. Prior to Mirum, he held senior leadership positions at Global Blood Therapeutics (now Pfizer Inc.) and Onyx Pharmaceuticals (now Amgen, Inc.), bringing valuable experience in advancing and commercializing innovative therapies.
  
  
• Appointed Jeff Held as Chief Legal Officer: In September 2026, MBX appointed Jeff Held, J.D., as Chief Legal Officer. Mr. Held brings more than 30 years of legal, compliance and executive leadership experience across the biotechnology, life sciences and healthcare industries, including prior leadership roles at Zenas BioPharma and Deciphera Pharmaceuticals.
  
  

Third Quarter 2026 Financial Results

• Cash and Cash Equivalents and Marketable Securities: As of September 30, 2026, MBX had cash, cash equivalents and marketable securities of $481.6 million, which reflects net proceeds of $97.6 million from the sale of common stock under the Company’s at-the-market (ATM) sales agreement. Based on its current operating plan, the Company expects the combined cash, cash equivalents and marketable securities balance to fund operations into 2029.
  
  
• R&D Expenses: Research and development expenses for the three months ended September 30, 2026, were $32.0 million, compared to $19.3 million for the same period in 2025. The increase of $12.7 million was driven by an increase in start-up costs related to the canvuparatide Phase 3 clinical trial which was initiated in the third quarter of 2026, ongoing conduct of the canvuparatide Phase 2 open-label extension clinical trial, ongoing conduct of the MBX 4291 Phase 1 clinical trial and timing of preclinical and IND-enabling activities related to MBX 5765 and MBX 6180.
  
  
• G&A Expenses: General and administrative expenses for the three months ended September 30, 2026, were $34.3 million, compared to $4.7 million for the same period in 2025. The increase of $29.6 million was driven by higher personnel-related costs, including $20.8 million of stock-based compensation expense related to the modification of awards for the Company’s former chief executive officer, and other higher personnel-related costs resulting from continued expansion of both the Company’s executive leadership team and general infrastructure to support growth in the Company’s operations.
  
  
• Net Loss: Net loss for the three months ended September 30, 2026, was $62.4 million compared to a net loss of $21.6 million for the same period in 2025.
  
  
  

About MBX Biosciences

MBX Biosciences is a biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities. The Company’s pipeline includes canvuparatide for the treatment of chronic hypoparathyroidism in Phase 3 development; and an obesity portfolio that includes MBX 4291 in Phase 1 development and MBX 5765 and MBX 6180 in preclinical development, as well as additional discovery candidates. The Company is based in Carmel, Indiana and Burlington, Massachusetts. To learn more, please visit the company website at www.mbxbio.com and follow it on LinkedIn.

About MBX’s Proprietary Precision Endocrine Peptide (PEP™) Platform

MBX was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, the Company designed its proprietary Precision Endocrine Peptide™ (PEP™) platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences’ expectations regarding the further advancement of its pipeline of programs in endocrine and metabolic disorders, including enrollment in the pivotal Phase 3 trial of canvuparatide; the potential for canvuparatide to be a once-weekly potentially best-in-class PTH replacement therapy; the expected timing of the Phase 1 readout for MBX 4291; statements related to MBX 4291 and its design to deliver once-monthly dosing and improved gastrointestinal tolerability; IND-enabling studies of MBX 5765; preclinical data for MBX 6180; the contributions of new directors or officers; the potential for MBX Biosciences to develop therapies for obesity dosed once monthly; and expectations regarding MBX Biosciences’ uses of capital, expenses and financial results, including the anticipated cash runway timing.

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to the Company’s research and development activities; MBX Biosciences’ ability to execute on its strategy including obtaining the requisite regulatory approvals on the expected timeline, if at all; uncertainties relating to preclinical and clinical development activities; the Company’s dependence on third parties to conduct clinical trials, manufacture its product candidates and develop and commercialize its product candidates, if approved; MBX Biosciences’ ability to attract, integrate and retain key personnel; risks related to the Company’s financial condition and need for substantial additional funds in order to complete development activities and commercialize a product candidate, if approved; risks related to regulatory developments and approval processes of the U.S. Food and Drug Administration and comparable foreign regulatory authorities; risks related to establishing and maintaining MBX Biosciences’ intellectual property protections; risks related to the competitive landscape for MBX Biosciences’ product candidates; as well as other risks described in “Risk Factors,” in MBX Biosciences’ Quarterly Report on Form 10-Q for the three months ended September 30, 2026, Annual Report on Form 10-K for the year ended December 31, 2025, as well as subsequent filings filed with the Securities and Exchange Commission (SEC). MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

MBX Biosciences uses and intends to continue to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor the Company's Investor Relations website, in addition to following the Company's press releases, SEC filings, public conference calls, presentations, and webcasts.

Media Contact:
Alexandra Weingarten
MBX Biosciences
aweingarten@mbxbio.com

Investor Contact:
Pete De Spain
MBX Biosciences
pdespain@mbxbio.com

MBX BIOSCIENCES, INC.
SELECTED FINANCIAL INFORMATION
		(Unaudited)
Statements of Operations Data:		Three months ended September 30,								Nine months ended September 30,
(in thousands, except per share and per share data)			2026				2025				2026				2025
Operating expenses:
Research and development		$	32,048			$	19,270			$	81,507			$	59,400
General and administrative			34,295				4,656				53,032				12,860
Total operating expenses			66,343				23,926				134,539				72,260
Loss from operations			(66,343	)			(23,926	)			(134,539	)			(72,260	)
Interest and other income, net			3,922				2,308				11,506				7,351
Net loss		$	(62,421	)		$	(21,618	)		$	(123,033	)		$	(64,909	)
Net loss per common share, basic and diluted		$	(1.29	)		$	(0.63	)		$	(2.58	)		$	(1.93	)
Weighted average number of common shares outstanding used in computation of net loss per common share, basic and diluted			48,559,266				34,198,597				47,617,875				33,688,669
										(Unaudited)
Balance Sheets Selected Financial Data:										September 30,				December 31,
(in thousands)											2026				2025
Cash, cash equivalents and marketable securities										$	481,594			$	373,705
Working capital(1)											467,595				366,044
Total assets											500,618				385,144
Total liabilities											27,671				15,921
Accumulated deficit											(347,509	)			(224,476	)
Total stockholders' equity											472,947				369,223
(1) Working capital is defined as total current assets less total current liabilities. See our financial statements and the related notes thereto included in our Quarterly Report on Form 10-Q for the Quarter Ending September 30, 2026 and Year Ending December 31, 2025 for further details regarding our current assets and current liabilities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How long does MBX Biosciences expect its cash to fund operations?

MBX expects its cash, cash equivalents and marketable securities to fund operations into 2029, based on its current operating plan. The balance was $481.594 million at September 30, 2026.

When will MBX Biosciences report its next MBX 4291 trial data?

MBX remains on track to report unblinded 12-week Phase 1 Part C, Cohort 1 data in Q4 2026. MBX 4291 is an obesity drug candidate designed for once-monthly dosing.

What dosing regimen is MBX Biosciences testing in MBX 4291 Cohort C1?

Cohort C1 is evaluating 30 mg once weekly for four weeks, followed by 120 mg and 180 mg once monthly. Participants are adults with a body mass index of at least 30 kg/m2.

What drove MBX Biosciences’ third-quarter 2026 administrative expense increase?

Higher personnel-related costs drove the increase, including $20.8 million of stock-based compensation related to modifications of awards for the former chief executive officer. Expansion of the executive leadership team and general infrastructure also contributed.